These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 12972635)
1. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Chang TL; Chang CH; Simpson DA; Xu Q; Martin PK; Lagenaur LA; Schoolnik GK; Ho DD; Hillier SL; Holodniy M; Lewicki JA; Lee PP Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11672-7. PubMed ID: 12972635 [TBL] [Abstract][Full Text] [Related]
2. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Liu X; Lagenaur LA; Lee PP; Xu Q Appl Environ Microbiol; 2008 Aug; 74(15):4626-35. PubMed ID: 18539799 [TBL] [Abstract][Full Text] [Related]
3. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Liu X; Lagenaur LA; Simpson DA; Essenmacher KP; Frazier-Parker CL; Liu Y; Tsai D; Rao SS; Hamer DH; Parks TP; Lee PP; Xu Q Antimicrob Agents Chemother; 2006 Oct; 50(10):3250-9. PubMed ID: 17005802 [TBL] [Abstract][Full Text] [Related]
4. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. Pusch O; Kalyanaraman R; Tucker LD; Wells JM; Ramratnam B; Boden D AIDS; 2006 Oct; 20(15):1917-22. PubMed ID: 16988512 [TBL] [Abstract][Full Text] [Related]
5. Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus. Marcobal A; Liu X; Zhang W; Dimitrov AS; Jia L; Lee PP; Fouts TR; Parks TP; Lagenaur LA AIDS Res Hum Retroviruses; 2016; 32(10-11):964-971. PubMed ID: 26950606 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of infection and transmission of HIV-1 and lack of significant impact on the vaginal commensal lactobacilli by carbohydrate-binding agents. Petrova MI; Mathys L; Lebeer S; Noppen S; Van Damme EJ; Tanaka H; Igarashi Y; Vaneechoutte M; Vanderleyden J; Balzarini J J Antimicrob Chemother; 2013 Sep; 68(9):2026-37. PubMed ID: 23640125 [TBL] [Abstract][Full Text] [Related]
7. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Vangelista L; Secchi M; Liu X; Bachi A; Jia L; Xu Q; Lusso P Antimicrob Agents Chemother; 2010 Jul; 54(7):2994-3001. PubMed ID: 20479208 [TBL] [Abstract][Full Text] [Related]
8. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Lagenaur LA; Sanders-Beer BE; Brichacek B; Pal R; Liu X; Liu Y; Yu R; Venzon D; Lee PP; Hamer DH Mucosal Immunol; 2011 Nov; 4(6):648-57. PubMed ID: 21734653 [TBL] [Abstract][Full Text] [Related]
9. Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. Yamamoto HS; Xu Q; Fichorova RN BMC Microbiol; 2013 Jan; 13():4. PubMed ID: 23298379 [TBL] [Abstract][Full Text] [Related]
10. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. Martín J; LaBranche CC; González-Scarano F J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346 [TBL] [Abstract][Full Text] [Related]
11. Blocking HIV-1 Infection by Chromosomal Integrative Expression of Human CD4 on the Surface of Lactobacillus acidophilus ATCC 4356. Wei W; Wiggins J; Hu D; Vrbanac V; Bowder D; Mellon M; Tager A; Sodroski J; Xiang SH J Virol; 2019 Apr; 93(8):. PubMed ID: 30728264 [No Abstract] [Full Text] [Related]
12. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein. Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111 [TBL] [Abstract][Full Text] [Related]
13. Shedding of HIV-1 subtype E in semen and cervico-vaginal fluid. Sutthent R; Chaisilwattana P; Roongpisuthipong A; Wirachsilp P; Samrangsarp K; Chaiyakul P; Puthavathana P; Wasi C J Med Assoc Thai; 1997 Jun; 80(6):348-57. PubMed ID: 9240008 [TBL] [Abstract][Full Text] [Related]
14. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody. Hou W; Fang C; Liu J; Yu H; Qi J; Zhang Z; Yuan R; Xiong D; Gao S; Adam Yuan Y; Li S; Gu Y; Xia N Antiviral Res; 2015 Oct; 122():101-11. PubMed ID: 26259811 [TBL] [Abstract][Full Text] [Related]
15. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide. Jiang A; Fisher H; Pomerantz RJ; Dornburg R Hum Gene Ther; 1999 Nov; 10(16):2627-36. PubMed ID: 10566890 [TBL] [Abstract][Full Text] [Related]
16. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. Zhao Q; Lu H; Schols D; De Clercq E; Jiang S AIDS Res Hum Retroviruses; 2003 Nov; 19(11):947-55. PubMed ID: 14678601 [TBL] [Abstract][Full Text] [Related]
17. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1. Esser U; Speck RF; Deen KC; Atchison RE; Sweet R; Goldsmith MA AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1845-54. PubMed ID: 11118070 [TBL] [Abstract][Full Text] [Related]
18. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells. Xiao X; Kinter A; Broder CC; Dimitrov DS Exp Mol Pathol; 2000 Jun; 68(3):133-8. PubMed ID: 10816381 [TBL] [Abstract][Full Text] [Related]
19. Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry. Bourgeois R; Mercier J; Paquette-Brooks I; Cohen EA Retrovirology; 2006 Jun; 3():31. PubMed ID: 16762062 [TBL] [Abstract][Full Text] [Related]